Showing 101-110 of 454 results
The Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales. Agreement enables Helsinn to expand into oncology therapeutics with new Phase III-ready asset
Findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer (NSCLC).
Helsinn, the Swiss Group focused on building quality cancer care products, and Grünenthal Group have announced today that they have signed an exclusive agreement for the registration, marketing, promotion and sales by Grupo Grünenthal Chile of Akynzeo®, the oral fixed combination of netupitant and palonosetron, developed for the prevention of chemotherapy-induced nausea and vom...
The CPhI World Wide Annual Meeting takes place in Barcelona from 4 to 6 October 2016.
In the Group’s 40th year of operations, Helsinn launched "The Helsinn Investment Fund" applying its fundamental core values of quality, integrity and respect, and drawing on 40 years’ expertise in research and development and commercialization of therapeutic candidates in cancer care, pain and inflammation and gastroenterology. The fund aims to help companies with innovative te...
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that long-term survival and response data from a Phase II clinical study of Pracinostat and azacitidine in older patients with acute myeloid leukemia ha...
On Friday November 18, 2016, 11 students received the Helsinn AdvancedSynthesis 2016/2017 Education Scholarship of 5.000.-CHF each, for a total of 55.000 CHF *********************************************************************************** venerdì 18 novembre 2016, sono stati premiati i giovani vincitori delle 11 Borse di Studio Helsinn Advanced Synthesis per l’anno scolastic...
Helsinn Integrative Care, Helsinn’s business unit focused on evidence-based, non-pharmaceutical cancer supportive care products, today announces that Xonrid® Gel, a topical gel for radiotherapy-induced dermatitis, already classified as a medical device in the EU, has received 510(K) FDA clearance in the US. This now allows Xonrid® Gel to be marketed in the US for the management...
Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016